Delivering Innovative Best-In Class NGS Sequencing Technologies
BioCat's partner Celemics is a biotech company located in Seoul, Korea, developing innovative NGS-based solutions through novel sequencing technology to disrupt the paradigm of the medicine, biopharma, synthetic biology, and microbiome industries. Founded in 2010, Celemics is focused on providing target enrichment panels to Europe and Asia for various applications including oncology, inherited disease and genetic marker discovery.
Celemics has developed the MSSIC platform to provide customized target capture probes with advanced genome analysis capabilities to accelerate drug discovery for immune profiling and antibody library sequencing purposes. As a manufacturer of hybridization captured target enrichment kits for NGS applications, Celemics secured itself as one of the frontrunners in the global genetic testing market.
Celemics offers defined panels and customized target enrichment kits in the IVD and RUO sectors with remarkable synthetic probe rebalancing technologies under stringent quality management systems (ISO 9001, ISO 13485, GMP).